Topical mitomycin-c for partially excised conjunctival squamous cell carcinoma

Uso de mitomicina C em neoplasia intra-epitelial córneo-conjuntival: modalidades de abordagem - relato de casos

“…Ressalte-se que o exame histopatológico foi realizado após os ciclos de MMC a 0,04% (quimiorredução pré-operatória). Nessas circunstâncias, o estudo histopatológico pode até não detectar as células neoplásicas, que podem ter sido erradicadas pela quimioterapia prévia (21) . As complicações do uso tópico da MMC podem ser dor ocular, hiperemia conjuntival e palpebral, erosões epiteliais focais, fotossensibilidade, blefaroespasmo e oclusão do ponto lacrimal inferior (4) .…”

Conjunctival Intraepithelial Neoplasia – Clinical Presentation, Diagnosis and Treatment Possibilities

“…Topical MMC 0.02% or 0.04% 4 times daily in 7 to 14-day for two cycles have been successfully employed for preoperative chemoreduction and to manage recurrent and residual tumors following surgical resection (Shields et al, 2002), (Frucht-Pery et al, 2002), (Shields et al,2005). MMC had been effectively used to treat primary CIN, with reported success rates between 85% (Wilson et al, 1997) and 100% (Frucht-Pery & Rozenmam, 1994), (Ramos-Lopez et al, 2004).…”

Neoadjuvant topical mitomycin C chemotherapy for conjunctival and corneal intraepithelial neoplasia

“…[6][7][8][9] By using topical neoadjuvant chemotherapy the advantages of surgical excision and of chemotherapy can be exploited in the most effective way. The surgical excision is limited, histopathologic diagnosis can be confirmed, the risk of keratoconjunctivitis is minimized, and the risk of postoperative tumour recurrence may be reduced.…”